References
- 1. Ivanisević P, Bojić L, Tomić S, et al. Clinico-epidemiological analysis of choroidal melanoma in Split Area, Croatia. Acta Med Croatica. 2011;65:257-261.
- 2. Uysal IÖ, Misir M, Polat K, et al. Primary malignant melanoma of the nasal cavity. J Craniofac Surg. 2012;23:2-5.10.1097/SCS.0b013e318242057522337451
- 3. Yamamura K, Kondo K, Moritani S. Primary malignant melanoma of the stomach: report of a case. Surg Today. 2012; 42:195-199.10.1007/s00595-011-0077-5326487022167480
- 4. Díaz-Sánchez A, Lara MÁ, Ortega P, et al. Colorectal melanoma: review of two distinct forms of presentation. Gastroenterol Hepatol. 2011; 34:83-88.10.1016/j.gastrohep.2010.10.01221333392
- 5. Ramos JA, Ramos WE, Ramos CV. Melanoma of the female urethra. Indian J Urol. 2011; 27:448-450.10.4103/0970-1591.91430326320922279307
- 6. Doublali M, Chouaib A, Khallouk A, et al. Primary malignant melanoma of prostate. Urol Ann. 2010;2:76-77.10.4103/0974-7796.65105294368520882159
- 7. Inoue M, Ishioka J, Kageyama Y, Fukuda H, Higashi Y. Primary malignant melanoma of the male urethra: a case report. Hinyokika Kiyo. 2008;54:305-308.
- 8. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.10.1056/NEJMoa1112302372451522356324
- 9. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41:2040-2059.10.1016/j.ejca.2005.03.03416125929
- 10. Anger M, Friedhofer H, Fukutaki MF, Ferreira MC, Landman G. Primary cutaneous melanoma: an 18-year study. Clinics (Sao Paulo). 2010;65:257-263.10.1590/S1807-59322010000300004284576520360915
- 11. Döme B, Hendrix JC, Paku S et al. Biological perspectives. Alternative vascularization mechanism in cancer. Pathology and therapeutic implications. Am J Pathol 2007;170:1-15.10.2353/ajpath.2007.060302176270917200177
- 12. Battisti R, Nunes DH, Weber AL, Schweitzer LC, Sgrot I. Evaluation of the epidemiological profi le and the mortality rate of the patients with primary cutaneous melanoma in Florianopolis - SC, Brazil. An Bras Dermatol. 2009;84:335-342.10.1590/S0365-0596200900040000319851664
- 13. Lugowska I, Kowalska M, Zdzienicki M, et al. The prognostic role of clinical factors, VEGF, IL-8 and sTNF-R1 in cutaneous melanomas at locoregional stage. Pol Merkur Lekarski. 2012;32:22-27.
- 14. Garbe C, Hauschild A, Volkenandt M, et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res. 2007;17:393-399.10.1097/CMR.0b013e3282f0503917992123
- 15. Eggermont AM, Spatz A, Lazar V, Robert C. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol. 2012;24:137-140.
- 16. Kovacević P, Visnjić M, Vlajković M, Kovacević T, Visnjić A. Sentinel node biopsy for skin melanoma. Vojnosanit Pregl. 2009;66:657-662.10.2298/VSP0908657K
- 17. Ohata C, Tadokoro T, Itami S. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol. 2008;35:215-221.10.1111/j.1346-8138.2008.00447.x18419678
- 18. de Giorgi V, Gori A, Grazzini M, et al. Estrogens, estrogen receptors and melanoma. Expert Rev Anticancer Ther. 2011;11:739-747.10.1586/era.11.4221554049
- 19. Vaisanen A, Kuvaja P, Kallioinen M, et al. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum Pathol. 2011;42:1103-1111.10.1016/j.humpath.2010.11.01321334717
- 20. Helfrich I, Schadendorf D. Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance? Mol Oncol. 2011;5:137-149.
- 21. Mahabeleshwar GH, Byzova TV. Angiogenesis in Melanoma. Semin Oncol. 2007;34:555-565. 10.1053/j.seminoncol.2007.09.009236530618083379